University Malaya Medical Centre
Kuala Lumpur, Malaysia
NCT Number: NCT04862351
During this ongoing pandemic, there is a crucial need for innovative approaches to deliver CR programmes other than frequent face-to-face sessions at the centre-based CR to reduce the number of times people come close in contact with others or gathering in large groups. This is a single setting, 2-arm parallel randomised clinical trial which aims to examine the effects of technology-assisted interventions in hybrid cardiac rehabilitation (TecHCR) among the coronary heart disease patients. Eligible participants will be randomly assigned into either intervention group (IG) or control group (CG) in 1:1 ratio using the computerised permuted blocks, alternating block sizes of 4 or 6. All participants will be followed up for three months and six months with data collection at baseline, (T0), three-month (T1) and six-month (T2) time points.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Kuala Lumpur, Malaysia
In recent years, CR delivery platforms and approaches have been changing as technology has become an integral part of our daily lives. Some of the barriers to CR may be able to be tackled with the advancement of technology, as it provides an alternative to the traditional centre-based CR through virtual consultations and remote monitoring that may eliminate the hassle of face-to-face consultations, work and time conflicts. During this ongoing pandemic, there is a crucial need for innovative approaches to deliver CR programmes other than frequent face-to-face sessions at the centre-based CR to reduce the number of times people come close in contact with others or gathering in large groups.
The overall aim of this proposed study is to examine the effects of technology-assisted interventions in hybrid cardiac rehabilitation (TecHCR) among the coronary heart disease patients. The objectives are as followings:
With the attrition rate of 20%, a total of 160 eligible participants with 80 per group will be recruited. The control group receives usual care including outpatient medical follow-up with the cardiologists and dietician counselling before hospital discharge. Then, the participants will have their first follow-up by the physicians in cardiac rehabilitation clinic and followed by monthly follow-up. Subsequently, they will have weekly, centre-based supervised exercise training by physiotherapist and follow-up with occupational therapist for 12 weeks. In addition of the usual care of outpatient medical follow-ups and dietary education, the intervention group will receive 3 times supervised exercise in the centre, weekly upload of CR education (audio-visual video) on WhatsApp for six weeks (Week 1 to Week 6). The prescribed exercise will then be continued at home with a pedometer as the "cue to action" to be worn by the participant; he or she will be required to upload the data daily to the web app on the smartphone. Participants will also receive a weekly audio/video-conferencing follow-up (Week 1 to Week 12). The outcome measures include Socio-demographic and Clinical Data, Bandura's exercise self efficacy scale (ESE), Health Promoting Lifestyle Profile II (HPLP II), adherence referring to the attendance to 12 weeks (supervised exercise training) for CG, and attendance (3 times supervised exercise training) and upload of exercise data (for 9 weeks) to web app for IG; and 12-week assessment for both groups, exercise capacity by Exercise Stress Test measuring the metabolic equivalents METs) and Hospital Anxiety and Depression Scale (HADS). The data entry and analysis will be performed using the IBM Social Package Statistical Software (SPSS) version 26.0 with a p value < 0.05 will be consider significant of the result.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
3 times of supervised exercise training at the centre-based, outpatient cardiac rehabilitation clinic
weekly audio/video conference
weekly for 6 weeks, duration of video about 10-15 minutes
daily dietary and exercise log
6 times of supervised exercise training
Time frame: Baseline (T0) - at 0 week, before initiation of interventions
Using Bandura's Exercise Self-efficacy to determine the effects of TecHCR on self-efficacy related to exercise before intervention (baseline)
Time frame: post intervention (T1) - at 12 weeks after initiation of interventions
Using Bandura's Exercise Self-efficacy to determine the effects of TecHCR on self-efficacy related to exercise post intervention (at 3-month)
Time frame: 6-month post intervention (T2) - at 36 weeks after initiation of interventions
Using Bandura's Exercise Self-efficacy to determine the effects of TecHCR on self-efficacy related to exercise 3-month post intervention (T2) (at 6 month)
Time frame: Baseline (T0) - at 0 week, before initiation of interventions
Using Health-promoting lifestyle Profile II to determine the effects of TecHCR on health promoting behaviours
Time frame: post intervention (T1) - at 12 weeks after initiation of interventions
Using Health-promoting lifestyle Profile II to determine the effects of TecHCR on health promoting behaviours
Time frame: 6-month post intervention (T2) - at 36 weeks after initiation of interventions
Using Health-promoting lifestyle Profile II to determine the effects of TecHCR on health promoting behaviours
Time frame: Baseline (T0) - at 0 week, before initiation of interventions
Using Hospital Anxiety and Depression Scale to determine the effects of TecHCR on anxiety and depression
Time frame: post intervention (T1) - at 12 weeks after initiation of interventions
Using Hospital Anxiety and Depression Scale to determine the effects of TecHCR on anxiety and depression
Time frame: 6-month post intervention (T2) - at 36 weeks after initiation of interventions
Using Hospital Anxiety and Depression Scale to determine the effects of TecHCR on anxiety and depression
Time frame: Baseline (T0) - at 0 week, before initiation of interventions
to determine the effects of TecHCR on fasting low density lipoprotein (LDL), high density lipoprotein (HDL), total cholesterol (mmol/L)
Time frame: post intervention (T1) - at 12 weeks after initiation of interventions
to determine the effects of TecHCR on fasting low density lipoprotein (LDL), high density lipoprotein (HDL), total cholesterol (mmol/L)
Time frame: 6-month post intervention (T2) - at 36 weeks after initiation of interventions
to determine the effects of TecHCR on fasting low density lipoprotein (LDL), high density lipoprotein (HDL), total cholesterol (mmol/L)
Time frame: Baseline (T0) - at 0 week, before initiation of interventions
to determine the effects of TecHCR on systolic and diastolic blood pressure
Time frame: post intervention (T1) - at 12 weeks after initiation of interventions
to determine the effects of TecHCR on systolic and diastolic blood pressure
Time frame: 6-month post intervention (T2) - at 36 weeks after initiation of interventions
to determine the effects of TecHCR on systolic and diastolic blood pressure
Time frame: Baseline (T0) - at 0 week, before initiation of interventions
to determine the effects of TecHCR on BMI
Time frame: post intervention (T1) - at 12 weeks after initiation of interventions
to determine the effects of TecHCR on BMI
Time frame: 6-month post intervention (T2) - at 36 weeks after initiation of interventions
to determine the effects of TecHCR on BMI
Time frame: Baseline (T0) - at 0 week, before initiation of interventions
to determine the effects of TecHCR on waist circumference
Time frame: post intervention (T1) - at 12 weeks after initiation of interventions
to determine the effects of TecHCR on waist circumference
Time frame: 6-month post intervention (T2) - at 36 weeks after initiation of interventions
to determine the effects of TecHCR on waist circumference
Chinese University of Hong Kong
Other
Effectiveness of Technology-assisted Interventions in Hybrid Cardiac Rehabilitation (TechCR) Among Coronary Heart Disease Patients
Acronym: TechCR
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07468955
Arterial Occlusive Diseases, Arteriosclerosis
Kütahya, Center, Turkey (Türkiye)
View Trial DetailsNCT05099692
Cardiac Rehabilitation, Cardiovascular Diseases
Shenyang, Liaoning, China
View Trial DetailsNCT00552591
Cardiovascular Diseases, Coronary Disease
Ottawa, Ontario, Canada
View Trial DetailsNCT04465669
Angina Pectoris, Angina, Stable
Tyumen, Russia
View Trial Details